Business
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) and a consistent reduction in
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"\nData demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) and a consistent reduction in inflammation, oxidative stress, and enhanced Regulatory T cell (Treg) number and suppressive function in patients who were administered a combination of CTLA4-Ig Fusion Protein (CTLA4-Ig) and Low Dose Interleukin-2 (LD IL-2); \n\n\nPrior to initiating treatment, patients were declining at an average rate of -1.1 points per month on the ALSFRS-R rating scale- At the end of 6 months of treatment, the mean rate of change on the ALSFRS-R was +0.04 points per month.\n\n\n HOUSTON--(BUSINESS WIRE)--\nCoya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the publication of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neurology. The publication can be viewed here.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611572383/en/Disease progression remained relatively unchanged during the first 6 months of CTLA4-Ig/LD IL-2 treatment (Graphic: Business Wire)\nDr. Stanley Appel, MD, Edwards Distinguished Endowed Chair for ALS and Director, Johnson Center for Cellular Therapeutics at Houston Methodist stated, “The ability of the combination therapy to halt clinical progression in ALS for 24 weeks provides an important proof of concept for the protective role of Tregs while simultaneously suppressing inflammation. What is most gratifying is the concomitant reduction of the lipid peroxide 4-HNE as well as inflammatory cytokines. This study provides the basis for a large-scale double-blind placebo-controlled trial to establish potential therapeutic efficacy for ALS patients.”\n\n\nDr. Howard H. Berman, CEO of Coya Therapeutics, stated: “This publication illustrates a promising clinical signal of a novel biologic combination immunotherapy in ALS, a truly devastating condition with high unmet need. Our development of our ALS program continues, and Coya remains on track to file its Inve...